Skip to main content


We're creating a new version of this page. See preview

Volume 10 Supplement 2

Breast Cancer Research 2008

  • Poster presentation
  • Open Access

Matrix metalloproteinase-8 is a regulator of the clinical aggressiveness of mammary tumours

  • 1,
  • 1,
  • 2,
  • 2,
  • 2,
  • 3,
  • 3,
  • 4,
  • 4 and
  • 1
Breast Cancer Research200810 (Suppl 2) :P38

  • Published:


  • Breast Cancer
  • Tumour Grade
  • Lymph Node Involvement
  • Mammary Tumour
  • Normal Breast

Protease genes are involved in multiple steps of cancer progression, including cell growth, migration and angiogenesis. These genes are valuable as prognostic and/or diagnostic markers of disease and are potential therapeutic targets.

We used TaqMan® real-time quantitative PCR to conduct the first detailed quantitative expression profiling of the entire family of metalloprotease and serine protease genes and their inhibitors in breast cancer (over 380 genes). Using a bank of 60 samples (50 cancer and 10 normal mammary tissue) collected at the Norfolk and Norwich University Hospital [1] we have identified a number of genes that show significant disregulation in tumour samples compared with normal breast tissue. Expression correlates either positively or negatively with tumour grade in many genes.

A further cohort of 229 Dutch patients with more extensive clinical history [2] was profiled in a subset of the metalloproteinase genes. Among the genes that showed significant aberrant expression, Matrix metalloproteinase-8 (MMP8) emerged as a candidate to play a protective role during tumour progression. MMP8 was found to have significant prognostic value and was strongly correlated with prolonged survival. MMP8 is prognostic as a continuous variable for relapse-free survival (hazard ratio = 0.76, P = 0.045) and for overall survival (hazard ratio = 0.69, P = 0.025). Expression of MMP8 also correlated with lymph node involvement, reduced expression equating to greater nodal spread (P = 0.001). Expression of MMP8 was independent of tumour grade. These data show that MMP8 is prognostic in breast cancer, and suggest that the function of MMP8 antagonizes metastasis.



Supported by Breast Cancer Campaign.

Authors’ Affiliations

University of East Anglia, Norwich, UK
Universidad de Oviedo, Spain
University of London, UK
University Medical Center Nijmegen, The Netherlands


  1. Porter S, Scott SD, Sassoon EM, Williams MR, Jones JL, Girling AC, Ball RY, Edwards DR: Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin Cancer Res. 2004, 10: 2429-2440. 10.1158/1078-0432.CCR-0398-3.View ArticlePubMedGoogle Scholar
  2. Porter S, Span PN, Sweep FC, Tjan-Heijnen VC, Pennington CJ, Pedersen TX, Johnsen M, Lund LR, Rømer J, Edwards DR: ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. Int J Cancer. 2006, 118: 1241-1247. 10.1002/ijc.21476.View ArticlePubMedGoogle Scholar


© BioMed Central Ltd 2008